Transgenic animal models are genetically engineered organisms in which foreign genes are deliberately inserted, modified, or silenced to replicate specific human biological processes or diseases. These models are indispensable tools for biomedical research, enabling scientists to study disease mechanisms, genetic predispositions, and therapeutic responses under controlled, biologically relevant conditions.
As drug development becomes more complex and targeted, traditional research models often fail to capture the intricacies of human disease biology. Transgenic animals bridge this gap by offering highly predictive in vivo systems that support disease research, drug screening, toxicology evaluation, and gene function studies.
With the rise of precision medicine and personalized therapeutics, transgenic models have become central to understanding how genetic variability influences disease progression and treatment outcomes. Advances in gene-editing technologies such as CRISPR-Cas9 have further accelerated the development of highly accurate, human-like models, improving translational success while reducing late-stage clinical failures.
According to BIS Research, the global transgenic animal model market was valued at $2,796.0 Million in 2025 and is projected to reach $6,799.3 Million by 2035, reflecting the sustained reliance on genetically engineered models across pharmaceutical, biotechnology, and academic research pipelines.
Download the complete TOC and Request sample report
• Rising pharmaceutical and biotechnology research activities worldwide
• Increasing focus on precision medicine and genetically targeted therapies
• Rapid adoption of CRISPR/Cas-9 and next-generation sequencing technologies
• Growing need for predictive preclinical models to reduce clinical trial failures
• Expansion of biologics, immuno-oncology, gene, and cell therapy pipelines
• Integration of AI and big data analytics into preclinical research workflows
• High development, breeding, and maintenance costs of transgenic animal models
• Requirement for specialized facilities, skilled personnel, and pathogen-free environments
• Ethical concerns surrounding animal genetic modification and usage
• Regulatory complexity across regions for genetically engineered organisms
• Limited affordability and accessibility for small research institutions and startups
• August 2025: Taconic Biosciences collaborated with Cyagen Biosciences to expand researcher access to over 16,000 genetically engineered mouse models.
• July 2025: Biocytogen Pharmaceuticals upgraded its preclinical business, adding advanced humanized, immunodeficient, and transgenic animal models alongside integrated preclinical services.
• October 2024: Alloy Therapeutics entered an institutional licensing agreement with Scripps Research for its ATX-Gx platform supporting fully human antibody discovery.
• June 2024: Biocytogen received a U.S. patent for its RenLite platform, enabling efficient development of fully human antibodies with simplified CMC workflows.
• CRISPR/CAS-9
• Microinjections
• Embryonic Stem Cell Injections
• Others
• Rodent (Mice & Rats)
• Rabbits
• Pigs
• Others
• Drug Discovery and Development
• Disease Research
• Gene Function Studies
• Toxicology and Safety Testing
• Others
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest-of-Europe
• Asia-Pacific
o Japan
o India
o China
o Australia
o South Korea
o Rest-of-Asia-Pacific
According to the Principal Analyst at BIS Research: “The transgenic animal model market is gaining momentum, driven by rising pharmaceutical R&D investments, the expansion of precision medicine, and CRISPR-based innovation that enables faster, more accurate disease modeling. While high maintenance costs remain a challenge, long-term growth will favor companies that adopt automation and cost-efficient gene-editing platforms to improve accessibility and scalability.”
The market is forecast to grow at a CAGR of 9.29% from 2025 to 2035, reaching $6,799.3 Million by 2035.
Key players include Charles River Laboratories International, Creative Biolabs, Alloy Therapeutics, Inotiv, HuidaGene, genOway, OmniAb, Taconic Biosciences, Biocytogen Pharmaceuticals, Merck Group, and Janvier Group.
CRISPR/CAS-9 leads the market, while humanized and disease-specific animal models are increasingly adopted for precision medicine and advanced biologics development.
BIS Research delivers expert-led insights, detailed segmentation, competitive benchmarking, and strategic advisory across biotechnology, life sciences, and advanced research technologies.
